ESLA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Estrella Immunopharma Inc (ESLA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows weak technical indicators, no positive news catalysts, and poor financial performance. It is better to wait for clearer signals or improvements in the company's fundamentals before considering an investment.
The technical indicators are bearish. The MACD is negatively expanding, RSI is neutral, and moving averages suggest a downward trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 1.158, with key support at 1.033 and resistance at 1.282.
NULL. There are no recent news updates, no significant insider or hedge fund activity, and no recent congress trading data.
The stock's pre-market price dropped by 5.50%, and the regular market change was minimal at 0.92%. The financials show no revenue, significant net losses, and negative EPS, despite some YoY improvement.
In Q3 2025, the company reported no revenue growth, a net income of -$4,801,149 (up 922.54% YoY), and an EPS of -0.13 (up 44.44% YoY). Gross margin remains at 0%. The financials indicate a struggling company with no clear growth trends.
No analyst rating or price target data is available for ESLA.
